CRVS
What one share of Corvus Pharmaceuticals holds
Pharmaceutical Preparations
We are a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.
Corvus Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.62 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.52 |
| Cash and investments | $0.22 |
| Book value | $2.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$2.36 | $0.14 | −$1.95 | — | $6.35 |
| 2017 | — | −$2.72 | $0.01 | −$2.27 | — | $4.03 |
| 2018 | — | −$1.71 | $0.01 | −$1.50 | — | $3.76 |
| 2019 | — | −$1.59 | $0.00 | −$1.27 | — | $2.54 |
| 2020 | — | −$0.20 | $0.00 | −$1.18 | — | $2.54 |
| 2021 | — | −$1.03 | $0.00 | −$0.88 | — | $2.09 |
| 2022 | — | −$0.89 | $0.01 | −$0.59 | — | $1.21 |
| 2023 | — | −$0.56 | $0.00 | −$0.50 | — | $0.79 |
| 2024 | — | −$1.02 | — | −$0.42 | — | $0.48 |
| 2025 | — | −$0.53 | $0.00 | −$0.41 | — | $0.82 |